Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression.
William C EarnshawCarmen Ortega-SabaterNamitha ThampiNarcís Fernandez-FuentesMercedes Guerrero MurilloAlba Martínez-MorenoMeritxell VinyolesTalía Velasco-HernandezClara BuenoJuan L TrincadoIsabel GranadaDiana CamposCarles GiménezJudith M BoerMonique L den BoerGabriel F CalvoMireia CamósJose-Luis FusterPablo VelascoPaola BalleriniFranco LocatelliCharles G MullighanDiana Carolina Johanna SpieringsFloris FoijerVictor M Pérez-GarcíaPablo MenéndezPublished in: EMBO molecular medicine (2023)
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. Here, we elucidate the presence of CIN in aneuploid cB-ALL subtypes using single-cell whole-genome sequencing of primary cB-ALL samples and by generating and functionally characterizing patient-derived xenograft models (cB-ALL-PDX). We report higher rates of CIN across aneuploid than in euploid cB-ALL that strongly correlate with intraclonal chr-CNH and overall survival in mice. This association was further supported by in silico mathematical modeling. Moreover, mass-spectrometry analyses of cB-ALL-PDX revealed a "CIN signature" enriched in mitotic-spindle regulatory pathways, which was confirmed by RNA-sequencing of a large cohort of cB-ALL samples. The link between the presence of CIN in aneuploid cB-ALL and disease progression opens new possibilities for patient stratification and offers a promising new avenue as a therapeutic target in cB-ALL treatment.
Keyphrases
- copy number
- single cell
- acute lymphoblastic leukemia
- papillary thyroid
- mass spectrometry
- mitochondrial dna
- squamous cell
- rna seq
- genome wide
- dna methylation
- squamous cell carcinoma
- high throughput
- transcription factor
- allogeneic hematopoietic stem cell transplantation
- liquid chromatography
- cell cycle
- molecular docking
- high performance liquid chromatography
- replacement therapy
- early life
- high fat diet induced
- tandem mass spectrometry
- free survival